Treatment of patients with advanced gastrointestinal stromal tumor of small bowel: Implications of imatinib mesylate

Table 2 Prognosis of 55 advanced and metastatic small bowel GIST patients treated with or without imatinib meslyate

	Non-Glivec (%)(n = 33)			Imatinib meslyate (%)(n = 22)				P
	Re-resection (n = 6)	C/T (n = 5)	Conservative Treatment (n = 22)	CR (n = 0)	PR (n = 15)	SD (n = 4)	PD (n = 3)
PRS (m) (median/mean)	6.7/14.7			-/72.6				0.00001
Mean	36.2	4.8	9.6	75.6		31.6
Median	15.7	3.7	5.9	-		24.7
95% CI of mean	7.5-65.0	2.3-7.3	6.1-13.0	67.5-87.0		22.0-41.2
Log-rank (p)	0.048			0.462
OS (m) (median/mean)	33.6/49.2			137.7/128.9				0.00001
Mean	73.1	28.5	48.2	140.1		53.2
Median	47.5	23.5	33.2	137.7		50.9
95% CI of mean	27.0-119.3	18.7-38.4	30.3-66.1	136.7-143.3		50.0-56.4
Log-rank	0.189			0.083